The Tech& Bio: Weekly Brief

Here’s a tight weekly roundup mixing tech and biomed—headlines link out.

• Pfizer wins $10B fight for obesity-drug startup Metsera

A decisive move into the GLP-1 race, giving Pfizer a fresh shot at weight-loss medicines after setbacks in its own pipeline.  

• CRISPR therapy slashes LDL and triglycerides in patients

Early human data show big lipid drops; the companion paper details outcomes and safety endpoints in NEJM.  

• Personalized gene editing that helped one child now headed to a clinical trial

Researchers are adapting bespoke edits for multiple kids with ultra-rare mutations, testing how scalable “one-off” cures can be.  

• “CRISPR babies” debate reignites as a company floats embryo editing plans

A Nature report surveys scientists’ reactions and the shifting ethical landscape around heritable genome editing.  

• Braveheart Bio raises $185M to run late-stage trial for hypertrophic cardiomyopathy drug

Big financing to press a global pivotal program in a genetic heart disease with few options.  

• Colossal buys animal-cloning firm Viagen to fuel de-extinction push

A biotech-meets-frontier-tech gamble that raises fresh scientific and ethical questions.  

• Evolocumab shows benefit in high-risk patients without prior heart attack

New randomized data add clinical texture to PCSK9 inhibition’s role alongside statins.  

• FDA updates guidance around Regenerative Medicine Advanced Therapy (RMAT) designation

A timely primer for cell- and gene-therapy sponsors navigating expedited pathways.  

• WHO flags priorities and pressures in global immunization

SAGE notes funding gaps and trust erosion while countries scale newer vaccines.  

• DeepMind: new AI tools to map species, predict deforestation, and parse biosignals

Fresh research threads AI into biodiversity modeling and environmental health surveillance.